Skip to main content

MOTS-c vs Survodutide

Both MOTS-c and Survodutide are used for metabolic. Here's how their evidence, dosing, and regulatory status actually compare.

MOTS-c

Evidence B

Mitochondrial-derived peptide MOTS-c

A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.

View full MOTS-c profile →

Survodutide

Evidence A

Survodutide (BI 456906)

A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.

View full Survodutide profile →

Side-by-Side

AttributeMOTS-cSurvodutide
Evidence GradeBA
FDA StatusNot FDA-approved — research peptide; multiple early-phase clinical trialsNot FDA-approved — Phase 3 trials for obesity and MASH
Typical Dose5–10 mg, 2–3 times weekly (subcutaneous)Trial range: 0.6–6 mg weekly (subcutaneous)
Clinics Indexed226
Categoriesmetabolic, longevityweight-loss, metabolic

Key reported benefits — MOTS-c

  • Insulin sensitivity
  • Exercise capacity
  • Metabolic flexibility

Key reported benefits — Survodutide

  • Weight loss
  • MASH resolution
  • Glucose control

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons